GH Research develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies targeting psychiatric disorders. The company is advancing a multi-indication pipeline with inhalable and intravenous formulations, positioning itself in the emerging psychedelic-derived therapeutics market for treatment-resistant conditions.
Cyborg Score Rationale
GH Research demonstrates solid clinical progress with Phase 2b data supporting its lead candidate, substantial market capitalization (~$1.5B as of June 2026), and a focused therapeutic strategy in a growing psychiatric treatment segment. However, as a clinical-stage company without approved products or revenue, it carries inherent R&D risk.
Top Insights
Lead program GH001 met primary endpoints in Phase 2b TRD trial with -15.5 point placebo-adjusted MADRS reduction, demonstrating clinical efficacy
Company completed FDA IND hold resolution with no respiratory toxicity findings in non-rodent studies, clearing regulatory pathway forward
Analyst price target recently raised to $35 from $25 (May 2026), signaling confidence in pipeline advancement
Diversified pipeline includes GH002 (IV formulation) in Phase 1 and GH003 (intranasal candidate) in preclinical development across psychiatric indications
Named Competitors
Esketamine (Spravato) — FDA-approved intranasal ketamine for TRD
COMPASS Pathways Program — Psilocybin therapy development for treatment-resistant depression
MDMA-Assisted Therapy — MDMA-assisted psychotherapy for PTSD
Recent Developments
(May 2026) Cantor Fitzgerald raised price target to $35 from $25 and initiated coverage at Overweight
(February 2026) Completed $150 million public offering to fund clinical development
(2025) Stock identified as among best performing small-cap performers in 2025
Open the full interactive GH Research PLC report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.